Regeneron Reports 84-Week Pasatru Extension Results
In the Phase 3 OPTIMA extension, Pasatru showed zero new HO lesions from week 56 to 84 versus nine on placebo, with fewer clinician-assessed flare-ups and a generally consistent safety profile.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Pasatru reports zero new HO lesions in OPTIMA extension
Regeneron said adult FOP patients in the OPTIMA trial extension had zero new heterotopic ossification lesions.